BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 3321493)

  • 1. [Naftidrofuryl in the therapy of chronic arterial occlusive disease in the intermittent claudication stage].
    Valentin A; Karnik R; Stöllberger C; Slany J
    Vasa Suppl; 1987; 20():361-4. PubMed ID: 3321493
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical effectiveness of naftidrofuryl in intermittent claudication].
    Kriessmann A; Neiss A
    Vasa Suppl; 1988; 24():27-32. PubMed ID: 3062823
    [No Abstract]   [Full Text] [Related]  

  • 3. Naftidrofuryl for intermittent claudication: a double-blind controlled trial.
    Ruckley CV; Callam MJ; Ferrington CM; Prescott RJ
    Br Med J; 1978 Mar; 1(6113):622. PubMed ID: 343869
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of naftidrofuryl (Praxilene) on intermittent claudication.
    Waters KJ; Craxford AD; Chamberlain J
    Br J Surg; 1980 May; 67(5):349-51. PubMed ID: 6992910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of safety and efficacy of buflomedil and naftidrofuryl in the treatment of intermittent claudication.
    Rosas G; Cerdeyra C; Lucas MA; Parano JR; Villa JJ
    Angiology; 1981 May; 32(5):291-7. PubMed ID: 7235299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy of intermittent claudication in the IIb stage of arterial occlusive disease].
    Kriessmann A; Neiss A; Lutilsky L; Beermann M; Kramann B
    Med Welt; 1979 Jun; 30(23):888-91. PubMed ID: 459805
    [No Abstract]   [Full Text] [Related]  

  • 7. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication.
    Clyne CA; Galland RB; Fox MJ; Gustave R; Jantet GH; Jamieson CW
    Br J Surg; 1980 May; 67(5):347-8. PubMed ID: 6992909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of Dusodril-Pi in arterial occlusive diseases. A multicentric double-blind study].
    Becker HM; Elert O; Häring R; Maurer PC; Raithel D; Sperling M; Stockmann U; Storz LW; Hirche H
    Med Welt; 1979 Oct; 30(43):1602-6. PubMed ID: 514039
    [No Abstract]   [Full Text] [Related]  

  • 9. [Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].
    Maass U; Amberger HG; Böhme H; Diehm C; Dimroth H; Heidrich H; Heinrich F; Hirche H; Mörl H; Müller-Bühl U
    Dtsch Med Wochenschr; 1984 May; 109(19):745-50. PubMed ID: 6373217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Double-blind study of naftidrofuryl-hydrogen oxalate in peripheral arterial occlusive disease].
    Pohle W; Hirche H; Barmeyer J; Schümichen C; Hoffmann G
    Med Welt; 1979 Feb; 30(7):269-72. PubMed ID: 372733
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of naftidrofuryl in patients with intermittent claudication.
    Karnik R; Valentin A; Stöllberger C; Slany J
    Angiology; 1988 Mar; 39(3 Pt 1):234-40. PubMed ID: 3281516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
    Adhoute G; Bacourt F; Barral M; Cardon JM; Chevalier JM; Cuny A; Gillet M; Juhan C; Leguay G; Marion J
    Angiology; 1986 Mar; 37(3 Pt 1):160-7. PubMed ID: 3518547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous naftidrofuryl on transcutaneous oxygen pressure in severe peripheral vascular disease.
    Taggart I; Wishart GC; Cuschieri RJ; MacBain GC
    Angiology; 1989 Oct; 40(10):895-8. PubMed ID: 2802260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Naftidrofuryl in stages III and IV of peripheral arterial occlusive disease].
    Horsch S
    Vasa Suppl; 1988; 24():38-43. PubMed ID: 3212602
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study.
    Adhoute G; Andreassian B; Boccalon H; Cloarec M; Di Maria G; Lefebvre O; Mondine P; Plagnol P; Pointel JP; Quancard X
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S75-80. PubMed ID: 1369725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Naftidrofuryl in patients with multi-infarct dementia and Alzheimer's disease].
    Grossmann W; Standl A; May U
    Vasa Suppl; 1988; 24():48-55. PubMed ID: 3212603
    [No Abstract]   [Full Text] [Related]  

  • 17. [Preliminary results of a long-term double-blind study of naftidrofuryl and a placebo in patients with moderate Alzheimer-type senile dementia].
    Cucinotta D; Dall'Asta D; Benaglia F; Barbagallo M; Butturini L; Pioli G; Salomone M
    G Clin Med; 1985; 66(11-12):467-76. PubMed ID: 3835091
    [No Abstract]   [Full Text] [Related]  

  • 18. [Naftidrofuryl in the treatment of simple diabetic retinopathy. A double-blind study].
    Klein M; Hirche H
    Klin Monbl Augenheilkd; 1985 Sep; 187(3):195-201. PubMed ID: 3906248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Training by walking and drug therapy of peripheral arterial occlusive disease].
    Kiesewetter H; Blume J; Jung F; Gerhards M; Leipnitz G
    Vasa Suppl; 1987; 20():384-7. PubMed ID: 3321495
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of naftidrofuryl on intermittent claudication: a meta-analysis.
    Lehert P; Riphagen FE; Gamand S
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S81-6. PubMed ID: 1369727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.